Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01559-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Celia Fernández-Rubio und 5 weiteren Autor:innen. Beteiligte Einrichtung: ISTUN Institute of Tropical Health, Department of Microbiology and Parasitology, Universidad de Navarra, IdiSNA (Navarra Institute for Health Researc…. Hauptthemen laut MEDLINE: Leishmaniasis, Antiprotozoal Agents, Leishmania infantum, Leishmania mexicana. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Spanish Ministry of Science and Innovation, Fundación La Caixa, Fundación Roviralta and Ubesol.
Abstract (Originalsprache)
Leishmaniasis remains one of the main public health problems worldwide, with special incidence in the poorest populations. Selenium and its derivatives can be potent therapeutic options against protozoan parasites. In this work, 17 aryl selenoates were synthesized and screened against three species of Leishmania ( Leishmania major , Leishmania amazonensis , and Leishmania infantum ). Initial screening in promastigotes showed L. infantum species was more sensitive to selenoderivatives than the others. The lead Se-(2-selenocyanatoethyl) thiophene-2-carboselenoate ( 16 ) showed a half-maximal effective concentration of 3.07 µM and a selectivity index > 32.57 against L. infantum promastigotes. It was also the most effective of all 17 compounds, decreasing the infection ratio by 90% in L. infantum -infected macrophages with amastigotes at 10 µM. This aryl selenoate did not produce a hemolytic effect on human red blood cells at the studied doses (10–100 µM). Furthermore, the gene expression of infected murine macrophages related to cell death, the cell cycle, and the selenoprotein synthesis pathway in amastigotes was altered, while no changes were observed in their murine homologs, supporting the specificity of Compound 16 against the parasite. Therefore, this work reveals the possible benefits of selenoate derivatives for the treatment of leishmaniasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ISTUN Institute of Tropical Health, Department of Microbiology and Parasitology, Universidad de Navarra, IdiSNA (Navarra Institute for Health Research), Navarra, Spain.
- ISTUN Institute of Tropical Health, Department of Pharmaceutical Sciences, Universidad de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.
ORCID-Profile: Mercedes Rubio-Hernández, Silvia Pérez-Silanes
Förderung
- Spanish Ministry of Science and Innovation
- Fundación La Caixa
- Fundación Roviralta and Ubesol
- Spanish Ministry of Universities
Zitieren
APA
Fernández-Rubio, C., Rubio-Hernández, M., Alcolea, V., Burguete-Mikeo, A., Nguewa, P. A., & Pérez-Silanes, S. (2024). Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01559-23
Vancouver
Fernández-Rubio C, Rubio-Hernández M, Alcolea V, Burguete-Mikeo A, Nguewa PA, Pérez-Silanes S. Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01559-23
BibTeX
@article{FernndezRubio2024,
author = {Fernández-Rubio, Celia and Rubio-Hernández, Mercedes and Alcolea, Verónica and Burguete-Mikeo, Aroia and Nguewa, Paul A and Pérez-Silanes, Silvia},
title = {Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01559-23}
}
EUVIMED